Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this double-blind, ...

Ricky Mulvey: Berkshire Hathaway is sitting on more cash than any company in history. You're listening. It's Motley Fool ...